Application of neomycin, neomycin derivative and composition thereof
Through the antibacterial and angiopoietin inhibitory effects of neomycin and its derivatives, combined with new wound healing materials, a preparation for wound healing was developed, which solved the problem of single function and poor effect of existing products, significantly accelerated the Wound healing process.
Patent Information
- Application Number
- CN202411057300.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
The existing products that promote wound healing have single functions and poor results, poor treatment of refractory wounds, and may cause secondary injuries.
Using neomycin and its derivatives, through its antibacterial properties and inhibitory properties of angiopoietin, hinders the binding of angiopoietin to its receptors, promotes cell proliferation, develops a preparation for treating tissue damage, repair and regeneration, and combines new wounds in the market Healing material for a variety of wounds and wound healing.
The wound healing process is significantly accelerated, and by inhibiting bacteria and promoting cell proliferation, improving the formation of granulation tissue and covering the epithelial layer, it solves the problems of wounds and wound healing, and is highly safe.
Smart Images

Figure CN118976035A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to the application of neomycin, neomycin derivatives and compositions thereof. Background Art
[0002] Wound healing is a complex and orderly biological process, which is mainly divided into the following stages: 1. Coagulation stage: At the beginning of wound formation, due to bleeding caused by ruptured blood vessels, the body quickly initiates a variety of physiological reactions, such as reflex spasm of vascular smooth muscle, activation of vasoactive substances, formation of fibrin clots, and participation in hemostasis. Platelets play a key role in coagulation. They not only quickly aggregate and adhere to the wound site and participate in hemostasis, but also promote the production of growth factors (such as transforming growth factor-β, epidermal growth factor and insulin growth factor, etc.) and pro-inflammatory factors, attracting inflammatory cells and fibroblasts to migrate to the wound. 2. Inflammatory stage: This stage is the key to wound healing and usually begins within hours of wound formation. In the early stage, the immune system is activated, and neutrophils infiltrate the wound to resist bacterial infection, prevent infection, and create a favorable environment for repair. Subsequently, monocytes infiltrate and transform into macrophages, which have bactericidal and pro-inflammatory effects in the early stage, can phagocytose pathogens and remove cell debris, and secrete cytokines and growth factors (such as fibroblast growth factor FGFs, vascular endothelial growth factor VEGF, etc.) to promote granulation tissue and angiogenesis, helping the wound transition to the next stage. Excessive reaction during the inflammatory phase may lead to pathological healing and scarring, while insufficient reaction is not conducive to repair. 3. Proliferation phase: The newly formed extracellular matrix (ECM) supports cell migration, and granulation tissue composed of fibroblasts, new capillaries, and inflammatory cells is formed at the bottom of the wound to fill the wound defect. This moist tissue is prone to bleeding, so dressings are needed to provide barrier protection. Keratinocytes proliferate and migrate in the wound area, and re-epithelialization is an important sign of early wound repair. Fibroblasts and endothelial cells are key cells. Fibroblasts are responsible for the deposition and remodeling of ECM and regulate the secretion of growth factors and cytokines. They also migrate to the center of the wound and differentiate into myofibroblasts, shrinking the wound by traction. Endothelial cells proliferate and migrate under the action of angiogenic signals (such as VEGF, FGF, TGF-β and angiopoietin), forming new blood vessels to provide nutrients and oxygen to the wound. 4. Remodeling phase: In this stage, granulation tissue is replaced by normal connective tissue.
[0003] Neomycin is an aminoglycoside antibiotic purified from the product of Streptomyces freundii. It is currently a widely used antibiotic in clinical practice, mainly used to treat various infections caused by sensitive bacteria. Neomycin is insoluble in organic solvents and can maintain a stable antibacterial effect in an environment with a pH value between 2 and 9, but its efficacy will be greatly reduced when heated with acidic substances.
[0004] There are many products on the market that promote wound healing, but most of them have various problems such as single function, poor wound healing effect, poor effect on treating refractory wounds and causing secondary damage to the wound, and some products cause redness and itching of the wound after use. Summary of the invention
[0005] In order to solve the problem of wound healing in vivo and in vitro, refractory wounds and wounds, the first purpose of the present invention is to provide a use of neomycin, neomycin derivatives and their compositions in the preparation of preparations for treating tissue damage, repair and regeneration. The preparation is based on the strong antibacterial properties of neomycin, neomycin derivatives and their compositions, and the effective inhibitory properties of neomycin, neomycin derivatives and their compositions on angiogenin, which hinders the binding of angiogenin to its receptors, promotes cell proliferation, and accelerates wound healing through the dual effects of antibacterial and promoting cell proliferation.
[0006] The second purpose of the present invention is to provide a preparation for treating tissue damage, repair and regeneration, which is combined with new wound healing materials on the market for application, and solves the problems of healing of various wounds and wounds.
[0007] The present invention is achieved through the following technical solutions:
[0008] Application of neomycin, neomycin derivatives and compositions thereof in the preparation of preparations for treating tissue damage, repair and regeneration.
[0009] Preferably, the neomycin derivative is neomycin amine.
[0010] The synthesis of neomycin amine can be prepared by using industrially produced neomycin sulfate as the starting material and a semi-synthetic method, which is divided into two steps: the first step is the acid-catalyzed alcoholysis reaction of neomycin sulfate to obtain neomycin hydrochloride; the second step is the amination reaction of neomycin hydrochloride to obtain neomycin amine. Neomycin derivatives can also be other neomycin or neomycin-based compounds with amino sugars as the basic skeleton and containing multiple aminoglycoside bonds.
[0011] Preferably, the tissue damage includes any one or more of skin damage, burns, scalds, gastrointestinal mucosal damage, nerve damage and other tissue damage.
[0012] A preparation for treating tissue damage, repairing and regenerating, comprising the neomycin, neomycin derivatives and a combination thereof.
[0013] Preferably, the preparation is used with neomycin, neomycin derivatives and combinations thereof alone or in combination with a pharmaceutically acceptable carrier, adjuvant or vehicle;
[0014] The effective concentration of the neomycin, neomycin derivatives and the combination thereof when used alone is 0.5 mg / mL to 5000 mg / mL.
[0015] Preferably, the preparation is any one or more of powder, dressing, gel, powder injection, spray preparation, and injection;
[0016] The pharmaceutically acceptable carrier, adjuvant or medium is any one or more combinations of physiological saline, sodium alginate and carbomer.
[0017] Preferably, the preparation comprises any one of neomycin sodium alginate gel, neomycin carbomer gel and neomycin chitosan carbomer gel.
[0018] Preferably, the preparation is administered by applying on the surface of tissues such as the skin and mucous membranes, or by subcutaneous, intramuscular, abdominal, intravenous or intracerebral administration.
[0019] Application of neomycin, neomycin derivatives and compositions thereof in the preparation of angiogenin inhibitors.
[0020] An angiogenin inhibitor comprises the neomycin, neomycin derivatives and a combination thereof.
[0021] The main antibacterial mechanism of neomycin is that it binds to 16S RNA in bacterial ribosomes, causing codon misreading on mRNA, interfering with the initiation, extension and translocation steps in the protein synthesis process, and ultimately causing the bacteria to be unable to synthesize protein and die. Neomycin can play a good antibacterial role against Gram-positive bacteria, Gram-negative bacteria, Mycobacterium tuberculosis, etc.
[0022] Angiogenin (ANG) is a member of the pancreatic ribonuclease (RNase) superfamily. It was originally identified as an angiogenic protein. ANG is widely expressed in the human body and has multiple biological functions, including regulating cell growth and survival, regulating innate immune responses, promoting hematopoietic regeneration, promoting neurogenesis, and preventing neurodegeneration. The ribonucleolytic activity of ANG is 10 -5 -10 -6times that of RNase A. However, this low and unique RNase activity is essential for its biological activities such as angiogenesis, hematopoietic regeneration, gastrointestinal mucosal regeneration and neuronal protection. The latest discovery of this function of ANG is related to its regulation of stem cells. ANG can keep hematopoietic stem cells, gastrointestinal stem cells and neural stem cells static and steady under emergency conditions, but proliferate and grow precursor stem cells under proliferative conditions. Neomycin and neomycin have been proven to be inhibitors of ANG, which hinder the binding of ANG to its receptors. Therefore, the application of neomycin and neomycin to the injured area can not only inhibit the reproduction of microorganisms around the wound, but also relieve the static state of stem cells and promote stem cell proliferation, thus accelerating wound healing through dual effects.
[0023] Compared with the prior art, the present invention has at least the following technical effects:
[0024] The present invention provides an application of neomycin, neomycin derivatives and compositions thereof in the preparation of preparations for treating tissue damage, repair and regeneration. The preparation is based on the fact that neomycin, neomycin derivatives and compositions thereof have extremely strong antibacterial properties, and at the same time, neomycin, neomycin derivatives and compositions thereof have effective inhibitory properties on angiogenin, hindering the binding of angiogenin to its receptor, promoting cell proliferation, and accelerating wound healing through the dual effects of inhibiting bacteria and promoting cell proliferation.
[0025] This preparation for treating tissue damage, repairing and regenerating is combined with new wound healing materials on the market for application, solving various problems of wound healing.
[0026] At the same time, the inventors used a mouse skin perforation full-thickness injury model and self-control experiments to strongly prove that in this model, neomycin and its preparations can significantly promote granulation tissue formation and epithelial coverage through their antibacterial, anti-inflammatory and promotion of collagen tissue proliferation, thereby accelerating wound healing. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is a schematic diagram showing that neomycin significantly promotes the healing of full-thickness wounds in mouse skin in Experimental Example 1;
[0028] Figure 2 Schematic diagram of neomycin promoting angiogenesis in the wound surface of full-thickness skin injury in mice in Experimental Example 1;
[0029] Figure 3 Representative pictures of HE staining histological observation of neomycin promoting the repair of full-thickness skin injury wounds in mice in Experimental Example 1;
[0030] Figure 4 This is a representative schematic diagram of Masson staining histological observation of neomycin promoting collagen tissue synthesis in full-thickness skin injury wounds of mice in Experimental Example 1;
[0031] Figure 5 Schematic diagram of the neomycin carbomer-based hydrogel prepared in Experimental Example 2;
[0032] Figure 6 Schematic diagram of neomycin carbomer-based hydrogel promoting full-thickness wound healing in mice skin in Experimental Example 2;
[0033] Figure 7 Schematic diagram of the neomycin-chitosan carbomer-based hydrogel prepared in Experimental Example 3;
[0034] Figure 8 Schematic diagram of neomycin-chitosan carbomer-based hydrogel promoting full-thickness wound healing in mice skin in Experimental Example 3;
[0035] Fig. 9 Schematic diagram of the synthesis process of neomycin derivative neomycinamine in Experimental Example 4;
[0036] Fig.10 Schematic diagram of the inhibition of angiogenin binding to receptor PlexinB2 by neomycin in Experimental Example 5;
[0037] Fig.11 This is a schematic diagram of the mechanism of neomycin / neomycin inhibiting the binding of angiogenin to the receptor PlexinB2 in Experimental Example 6. DETAILED DESCRIPTION
[0038] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0039] Example 1: Validation of neomycin promoting wound healing in full-thickness excision in mice.
[0040] 1) Experimental animal grouping and treatment: Trauma model mice were randomly divided into 2mg / mL, 5mg / mL and 10mg / mL neomycin treatment groups, with 5 mice in each dose group, and housed in separate cages. Corresponding wounds were made on the backs of mice, and the left and right were compared. The wound recovery between the control group (right side) and the treatment group (left side) was compared daily. The wounds of the control group were treated with normal saline every day, and the treatment group was treated with a medical cotton ball surface dressing containing different concentrations of neomycin saline solution, once a day, for 2 minutes each time. The effects of different concentrations of neomycin on wound healing were evaluated.
[0041] 2) Evaluation of wound healing: The wounds of mice were observed and photographed on the 3rd, 5th, 7th, 9th and 11th days of the mouse full-thickness infection model. The photos were analyzed using Image J software to measure the size of the wound. The wound healing rate per day after administration was calculated using the following formula: Wound healing rate = (wound area on the first day after modeling - wound area after administration) / wound area on the first day after modeling × 100%, and the wound healing effect was analyzed and compared.
[0042] 3) Observation and evaluation of wound blood vessels: On days 3, 5, 7, 9, and 11 after injury, mice were euthanized by myelotomy. Subsequently, the skin within 1 cm of the wound and its surrounding area was carefully lifted from under the deep fascia and completely removed. A flashlight was used as a light source to perform a light transmission test on the wound to observe and record the growth of blood vessels.
[0043] 4) HE staining of tissue sections: On days 0, 3, 5, 7, 9, and 11 of the experiment, the mice were euthanized and the skin tissue around the wound was collected. After collection, the tissue was first washed with saline to remove blood, then immersed in 4% formaldehyde solution for fixation, embedded, and 4 μm sections were made. The sections were routinely stained with HE, and observed and photographed under an optical microscope.
[0044] 5) Masson staining observation: The above 4 μm skin tissue sections were first stained with Weigert iron hematoxylin, then differentiated with acidic ethanol, blued with Masson bluing solution, stained with Ponceau fuchsin, treated with phosphomolybdic acid solution, dried, stained with aniline blue, and finally dehydrated and sealed for observation and photography under an optical microscope.
[0045] like Figure 1 Shown is a schematic diagram showing that neomycin significantly promotes the healing of full-thickness skin wounds in mice.
[0046] like Figure 1 The results showed that neomycin significantly promoted the healing of full-thickness wounds.
[0047] like Figure 2 Shown is a schematic diagram of neomycin promoting angiogenesis in the wound surface of full-thickness skin injury in mice.
[0048] like Figure 2 The results showed that neomycin promoted angiogenesis in the wound surface of full-thickness skin injury in mice.
[0049] like Figure 3 Shown are representative images of histological observations of HE staining and neomycin-promoted repair of full-thickness skin injury wounds in mice.
[0050] like Figure 3The results showed that neomycin promoted the repair of full-thickness skin wounds in mice, and HE staining histological observation was performed. The scale bars are 1000μm and 250μm respectively.
[0051] like Figure 4 Shown are representative images of Masson staining histological observations showing that neomycin promotes collagen tissue synthesis in full-thickness skin injury wounds in mice.
[0052] like Figure 4 The results showed that neomycin promoted the synthesis of collagen tissue in the full-thickness skin injury wound of mice, and Masson staining histological observation was performed. The scale bars are 100μm and 25μm respectively.
[0053] Example 2: Preparation of neomycin carbomer hydrogel and administration and comparative observation of full-thickness skin injury wounds in mice.
[0054] 1) Preparation of neomycin carbomer-based hydrogel: Carbomer 940: 1 g, ethanol: 5 g, glycerol: 5 g, polysorbate 80: 0.2 g, ethylparaben: 0.1 g, sodium hydroxide: 0.4 g.
[0055] 2) The preparation method is: mix carbomer, ethanol, glycerol, polysorbate and distilled water in a container and stir evenly. Subsequently, slowly add sodium hydroxide solution to the mixed carbomer solution and stir well to ensure uniform mixing, avoid local excessive alkalinity, and ensure chemical stability and physical properties during gel formation. Finally, continue to gradually add distilled water to 100mL while keeping stirring until the desired gel concentration and viscosity are reached. The stirred mixture needs to stand for a period of time to allow the gel to fully form and achieve a transparent and stable texture. After preparing the basic carbomer-based hydrogel, further add neomycin to the gel to reach a concentration of 10mg / mL and stir evenly. The prepared neomycin carbomer-based hydrogel is as follows Figure 5 shown.
[0056] 3) Experimental animal grouping and treatment
[0057] The trauma model mice were randomly divided into 2 groups, 6 in each group. All mice were made with a 1 cm diameter symmetrical wound on the back using a 1 cm punch. Group 1: Neomycin saline solution was applied to the left side of the back wound of the mice, and gentamicin saline was applied to the right side. Group 2: Neomycin carbomer hydrogel was applied to the left side of the mice, and gentamicin was applied to the right side. The recovery of the wound was observed and recorded daily, and the treatment effect was compared between the left and right sides.
[0058] like Figure 6 Shown is a schematic diagram of neomycin carbomer-based hydrogel promoting the healing of full-thickness skin wounds in mice.
[0059] like Figure 6 The results showed that neomycin carbomer-based hydrogel significantly promoted the healing of full-thickness skin wounds.
[0060] Example 3: Preparation of neomycin-chitosan carbomer hydrogel and its administration and comparative observation on full-thickness skin injury wounds in mice.
[0061] 1) Preparation of neomycin-chitosan carbomer-based hydrogel: After preparing the basic carbomer-based hydrogel as in Example 2, neomycin was further added to the gel to a concentration of 10 mg / mL and 100 μg / mL chitosan was added to obtain a neomycin carbomer-based hydrogel such as Figure 7 shown.
[0062] 2) Experimental animal grouping and treatment
[0063] The trauma model mice were randomly divided into 3 groups, 6 in each group. All mice were made with a 1 cm diameter symmetrical wound on the back using a 1 cm punch. Group 1: Neomycin saline solution was applied to the left side of the back wound of the mice, and gentamicin saline was applied to the right side. Group 2: Neomycin carbomer-based hydrogel was applied to the left side of the mice, and gentamicin was applied to the right side. Group 3: Chitosan Neomycin carbomer-based hydrogel (Neomycin-cs) was applied to the left side of the mice, and Neomycin carbomer-based hydrogel was applied to the right side. As above, the recovery of the wound was observed and recorded daily, and the left and right sides were compared to compare the treatment effect.
[0064] like Figure 8 Shown is a schematic diagram of neomycin-chitosan carbomer-based hydrogel promoting the healing of full-thickness skin wounds in mice.
[0065] like Figure 8 The results showed that chitosan-neomycin carbomer-based hydrogel was superior to neomycin carbomer-based hydrogel in promoting the healing of full-thickness skin wounds.
[0066] Example 4: Synthesis of neomycin derivative neomycinamine
[0067] like Fig. 9 As shown, the schematic diagram of the synthesis process of neomycin derivative neomycinamine.
[0068] The synthesis of the neomycin derivative neomycinamide can be prepared by using industrially produced neomycin sulfate as a starting material and a semi-synthetic method, which is divided into two steps: the first step is an acid-catalyzed alcoholysis reaction of neomycin sulfate to obtain neomycinamide hydrochloride; the second step is an amination reaction of neomycinamide hydrochloride to obtain neomycinamide.
[0069] Example 5: Neomycin / neomycin inhibits the binding of angiogenin (ANG) to the receptor PlexinB2
[0070] like Fig.10 Shown is a schematic diagram of the inhibition of ANG binding to receptors by neferol.
[0071] Figure A is a fitting curve diagram of the binding of ANG to LNCaP cell surface receptors.
[0072] The method is: first use an overdose of I 125 Mark ANG (final ANG and I 125 The binding capacity reached 1.1uCi / μg), LNCaP cells were 5×10 3 / 100μL was inoculated into a 96-well plate (15 wells for each of the control group and the synmycin group), cultured at 37℃ for 24h, pre-cooled and cultured at 4℃ for 10min the next day, 100μM synmycin was added, and the control group wells did not have synmycin. 125 -ANG (0.001-2.5 μg / mL) was added to the cells and cultured at 4°C for 30 min. The cells were harvested and washed three times with pre-cooled RPMI1640 cell culture medium. The radioactivity was detected with a γ counter, and the bound and unbound ANG were calculated.
[0073] Figure B is a schematic diagram showing that immunoprecipitation was used to further demonstrate that syndecanamide inhibits the binding of ANG to PlexinB2.
[0074] The method is as follows: first, COS-7 cells overexpressing PlexinB2 (the control is an empty plasmid without PlexinB2), and 2×10 9 Cells were lysed with RIPA lysis buffer, homogenized, and centrifuged at 100,000 g for 30 min to obtain cell membrane proteins. 1 μg / mL ANG was added and incubated at 4°C for 30 min. 10 μg / mL 26-2F anti-ANG antibody was incubated overnight, and DAB staining was used to detect ANG fragments bound to PlexinB2.
[0075] Fig.10 The results showed that 100 μM neomycin significantly inhibited the binding of ANG to the surface receptor of LNCaP cells. Radioactivity detection was used to verify that 100 μM neomycin effectively inhibited I 125 Labeled ANG binds to LNCaP cell surface receptors.
[0076] Example 6: Mechanism of action of neomycin / neomycinamine in inhibiting the binding of angiogenin to receptor PlexinB2
[0077] like Fig.11 The figure shows the schematic diagram of the mechanism of neomycin / neomycin inhibiting the binding of angiogenin (ANG) to the receptor PlexinB2.
[0078] The results showed that the pro-survival and anti-apoptotic functions of ANG are generated by hydrolysis of a class of bioactive small RNAs, namely tRNA-derived stress-induced small RNAs (tiRNAs), which inhibit global protein translation but allow internal ribosomes enter sequence (IRES)-mediated translation, a protein translation mechanism that preferentially selects anti-apoptotic and pro-survival genes. When cells are stressed, such as under oxidation, hypoxia and pressure, ANG is transferred to stress particles in the cytoplasm. Stress particles contain untranslated mRNA and RNA-binding proteins, which form a stop protein translation response when cells are stressed, thereby saving anabolic energy and promoting cell survival and quiescence under adverse conditions. Neomycin / neomycin inhibits the binding of angiogenin to the receptor PlexinB2, causing cells to lose quiescence and enter proliferation. For example, in skin cells, it can promote the proliferation of skin stem cells and promote growth and repair.
[0079] Neomycin, neomycin derivatives and their compositions play a good therapeutic role in the treatment of tissue damage, repair and regeneration. In the mouse back full-thickness skin injury model, neomycin and neomycin sodium alginate gel, neomycin carbomer gel and neomycin chitosan carbomer gel can accelerate the formation of granulation tissue and epithelial layer coverage through their antibacterial and anti-inflammatory effects and promotion of collagen tissue proliferation, thereby accelerating the overall process of wound healing.
[0080] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of neomycin, neomycin derivatives and their compositions in the preparation of preparations for treating tissue damage, repair and regeneration.
2. The use of neomycin, neomycin derivatives and compositions thereof according to claim 1 in the preparation of preparations for treating tissue damage, repair and regeneration, characterized in that: The neomycin derivative is neomycin amine.
3. Use of neomycin, neomycin derivatives and compositions thereof according to claim 1 in the preparation of preparations for treating tissue damage, repair and regeneration, characterized in that: The tissue damage includes any one or more of skin damage, burns, scalds, gastrointestinal mucosal damage, nerve damage and other tissue damage.
4. A preparation for treating tissue damage, repair and regeneration, characterized in that: Comprising the neomycin, neomycin derivatives and combinations thereof as claimed in claim 1.
5. A preparation for treating tissue damage, repair and regeneration according to claim 4, characterized in that: The preparation is used with neomycin, neomycin derivatives and combinations thereof alone or in combination with pharmaceutically acceptable carriers, adjuvants or vehicles; The effective concentration of the neomycin, neomycin derivatives and the combination thereof when used alone is 0.5 mg / mL to 5000 mg / mL.
6. A preparation for treating tissue damage, repair and regeneration according to claim 5, characterized in that: The preparation is any one or more of powder, dressing, gel, powder injection, spray preparation, and injection; The pharmaceutically acceptable carrier, adjuvant or vehicle is any one or more combinations of physiological saline, sodium alginate and carbomer.
7. A preparation for treating tissue damage, repair and regeneration according to claim 6, characterized in that: The preparation comprises any one of neomycin sodium alginate gel, neomycin carbomer gel and neomycin chitosan carbomer gel.
8. A preparation for treating tissue damage, repair and regeneration according to claim 7, characterized in that: The preparation is administered by applying on the surface of tissues such as skin and mucous membranes, or by subcutaneous, intramuscular, abdominal, intravenous or intracerebral administration.
9. Use of neomycin, neomycin derivatives and compositions thereof in the preparation of angiogenin inhibitors.
10. An angiogenin inhibitor, characterized in that Comprising neomycin, neomycin derivatives and combinations thereof as described in claim 9.
Citation Information
Cited By
Medicine for treating scald infection as well as preparation method and application thereof
CN119925399A
A medicine for treating scald infection and its preparation method and use
CN119925399B
